Business · 7 hours ago
GSK Shares Dive as Vaccine Sales Fall
Paul Huntley, CC BY-SA 2.0, via Geograph/Wikimedia Commons
Shares in GSK fell as much as 7% on Wednesday, making the drugmaker the biggest faller on the FTSE 100. Profit before tax dropped 19% to £1.9bn in the third quarter, with £318m of restructuring costs. Sales of its Shingrix shingles vaccine fell 5% and its RSV jab Arexvy slid 24%, though total turnover rose 5% to £8.9bn thanks to strong HIV and cancer sales.
Reported by The Guardian · How we write briefs